The first of these approaches utilizes virus-specific, receptor-mediated cell targeting based on addressing cell markers that are expressed in tumor cells, such as epidermal growth factor receptor (EGFR) and HER-2 (39). The gene discussed is ERBB2; the disease is neoplasm.